This article first appeared on GuruFocus .
Release Date: May 14, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Dare Bioscience Inc ( NASDAQ:DARE ) has a comprehensive pipeline focused exclusively on women's health, addressing critical gaps in care.
-
The company is launching its first direct product revenue with FloraSync LF5 in June 2026, marking a significant milestone.
-
Dare to Play, a first-of-its-kind topical arousal cream for women, has received enthusiastic reception from healthcare providers.
-
The company benefits from non-dilutive grant funding, which helps advance multiple programs while managing shareholder dilution.
-
Dare Bioscience Inc ( NASDAQ:DARE ) is strategically positioned with a dual-path approach, pursuing both 503b compounding and FDA approval for its products.
Negative Points
-
The launch of Dare to Play has faced delays due to state-specific registration activities and manufacturing readiness.
-
The company does not have 12 months of capital on hand and will need to raise additional funds.
-
There are some states that will not allow dispensing of Dare to Play until they review data from other states.
-
The company is still in the process of building its commercial infrastructure, which may impact the speed of market penetration.
-
Oviprine, a potential first-in-category product, still requires further clinical trials and FDA engagement, which could delay its market entry.
Q & A Highlights
Q: With regard to the Oviprine trial and the interplay between enrollment pace and cycles, what kind of impact could this have on the timing of the readout? A: Sabrina Martucci-Johnson, CEO: The timing could be affected by the number of women completing the cycles. We are not seeing changes in the safety signal over time, which is promising. We plan to engage with the FDA to discuss these findings, but I can't provide more specific insights on timing at this point.
Q: What factors have impacted the timing of the Dare to Play nationwide fulfillment? A: Sabrina Martucci-Johnson, CEO: We are working closely with Bravado, our 503 outsourcing facility, to ensure commercial readiness, which includes GMP compliance and state-specific registration activities. They are progressing well, with 28 registrations so far, but some states require additional data before allowing dispensing.
Q: How are you thinking about the cash runway at this point? A: Sabrina Martucci-Johnson, CEO: We have cash for grant-funded activities and general operations. Without considering projected revenue, we don't have 12 months of capital, so we will need to raise funds. However, future disbursements from grants and projected revenue from products are not included in this assessment.
Q: Can you elaborate on the strategic importance of product revenue for DARE? A: Marty Herring-Layton, Chief Accounting Officer: Product revenue will add a third leg to our funding strategy, alongside equity financing and non-dilutive grant funding. It ties directly to the value we deliver to patients and clinicians and is expected to grow with our commercial footprint, reinforcing our development mission.
Q: What are the next steps for DARE-HPV, and why is it significant? A: Sabrina Martucci-Johnson, CEO: DARE-HPV is advancing into a Phase 2 clinical study with ARPA-H funding. It targets a significant unmet need, as there is no FDA-approved pharmacologic treatment for high-risk HPV infections, which are the underlying cause of nearly all cervical cancer cases in the U.S.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
